Prognostic value of p53, glutathione S-transferase π, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 4097-4104

  Shiga, Hideaki ^a,d   Heath, Elizabeth I ^b   Rasmussen, Audrey A ^a   Trock, Bruce ^a   Johnston, Patrick G ^c   Forastiere, Arlene A ^b   Langmacher, Miles ^a   Baylor, Alfred ^a   Lee, Michele ^a   Cullen, Kevin J ^a,e  

^a GEORGETOWN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d KANAZAWA UNIVERSITY   (Japan)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GLUTATHIONE TRANSFERASE; THYMIDYLATE SYNTHASE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HEAD AND NECK NEOPLASMS; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033395108     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kish, J. A., Weaver, A., Jacobs, J., Cummings, G., and Al-Sarraf, M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer (Phila.), 53: 1819-1824, 1984.
2. Jacobs, C., Lyman, G., Velez-Garcia, E., Sridhar, K. S., Knight, W., Hochster, H., Goodnough, L. T., Mortimer, J. E., Einhorn, L. H., Schacter, L. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol., 10: 257-263, 1992.
3. Toohill, R. J., Anderson, T., Byhardt, R. W., Cox, J. D., Duncavage, J. A., Grossman, T. W., Haas, C. D., Haas, J. S., Hartz, A. J., and Libnoch, J. A. Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer: A preliminary report. Arch. Otolaryngol. Head Neck Surg., 113: 758-761, 1987.
4. Vokes, E. E., Panje, W. R., Mick, R., Kozloff, M. F., Moran, W. J., Sutton, H. G., Goldman, M. D., Tybor, A. G., and Weichselbaum, R. R. A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer (Phila.), 66: 206-213, 1990.
5. Martin, M., Hazan, A., Vergnes, L., Peytral, C., Mazeron, J. J., Senechaut, J. P., Lelievre, G., and Peynegre, R. Randomized study of 5 fluorouracil and cis platin as neoadjuvant therapy in head and neck cancer: A preliminary report. Int. J. Radiat. Oncol. Biol. Phys., 19: 973-975, 1990.
6. Spaulding, M. B., Fischer, S. G., and Wolf, G. T. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J. Clin. Oncol., 12: 1592-1599, 1994.
7. Cheung, A. Y., Rinehart, J., and Ruff, T. Locally advanced head and neck cancer: combined chemotherapy and radical radiation therapy for organ and function preservation (interim report). Radiology, 204: 207-210, 1997.
8. Browman, G. P. Evidence-based recommendations against neoadjuvant chemotherapy for routine management of patients with squamous cell head and neck cancer. Cancer Invest., 12: 662-670, 1994.
9. Rusch, V., Klimstra, D., Venkatraman, E., Oliver, J., Martini, N., Gralla, R., Kris, M., and Dmitrovsky, E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer. Res., 55: 5038-5042, 1995.
10. Righetti, S. C., Della Torre, G., Pilotti, S., Menard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C., Cornarotti, M., Oriana, S., Bohm, S., Bresciani, G. L., Spatti, G., and Zunino, F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res., 56: 689-693, 1996.
11. Buttitta, F., Marchetti, A., Gadducci, A., Pellegrini, S., Morganti, M., Carnicelli, V., Cosio, S., Gagetti, O., Genazzani, A. R., and Bevilacqua, G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br. J. Cancer, 75: 230-235, 1997.
12. Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F., Schultz, P. K., Cordon-Cardo, C., and Scher, H. I. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol., 13: 1384-1390, 1995.
13. Perego, P., Giarola, M., Righetti, S. C, Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., and Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res., 56: 556-562, 1996.
14. Mistry, P., and Harrap, K. R. Historical aspects of glutathione and cancer chemotherapy. Pharmacol. Ther., 49: 125, 1991.
15. Meister, A. Glutathione, ascorbate, and cellular protection. Cancer Res., 54 (Suppl. 7): 1969s-1975s, 1994.
16. Voehringer, D. W., McConkey, D. J., McDonnell, T. J., Brisbay, S., and Meyn, R. E. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc. Natl. Acad. Sci. USA, 95: 2956-2960, 1998.
17. Yellin, S. A., Davidson, B. J., Pinto, J. T., Sacks, P. G., Qiao, C., and Schantz, S. P. Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines [published erratum appears in Cancer Lett. 89: 229, 1995]. Cancer Lett., 85: 223-232, 1994.
18. Newkirk, K., Heffern, J., Sloman-Moll, E., Sessions, R. B., Rasmussen, A. A., Andrews, P. A., and Cullen, K. J. Glutathione content but not gamma glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines. Cancer Chemother. Pharmacol., 40: 75-80, 1997.
19. Dirven, H. A., van, O. B., and van, B. P. J. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res., 54: 6215-6220, 1994.
20. Dirven, H. A., Dictus, E. L., Broeders, N. L., van, O. B., and van, B. P. J. The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa. Cancer Res., 55: 1701-1706, 1995.
21. Ban, N., Takahashi, Y., Takayama, T., Kura, T., Katahira, T., Sakamaki, S., and Niitsu, Y. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res., 56: 3577-3582, 1996.
22. Bai, F., Nakanishi, Y., Kawasaki, M., Takayama, K., Yatsunami, J., Pei, X. H., Tsuruta, N., Wakamatsu, K., and Hara, N. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer (Phila.), 78: 416-421, 1996.
23. Lautier, D., Canitrot, Y., Deeley, R. G., and Cole, S. P. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol., 52: 967-977, 1996.
24. Chabner, B. A. Anticancer drugs. In: V. T. Devita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 325-417. Philadelphia: Lippincott, 1993.
25. Johnston, P. G., Lenz, H. J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., and Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55: 1407-1412, 1995.
26. Johnston, P. G., Mick, R., Recant, W., Behan, K. A., Dolan, M. E., Ratain, M. J., Beckmann, E., Weichselbaum, R. R., Allegra, C. J., and Vokes, E. E. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J. Natl. Cancer Inst., 89: 308-313, 1997.
27. Maguire, H. C., Jr., and Greene, M. I. The neu (c-erbB-2) oncogene. Semin. Oncol., 16: 148-155, 1989.
28. Beckhardt, R. N., Kiyokawa, N., Xi, L., Liu, T. J., Hung, M. C., el-Naggar, A. K., Zhang, H. Z., and Clayman, G. L. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg., 121: 1265-1270, 1995.
29. Langton-Webster, B. C., Xuan, J. A., Brink, J. R., and Salomon, D. S. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. Cell Growth Differ., 5: 1367-1372, 1994.
30. Arteaga, C. L., Winnier, A. R., Poirier, M. C., Lopez-Larraza, D. M., Shawver, L. K., Hurd, S. D., and Stewart. S. J. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res., 54: 3758-3765, 1994.
31. Johnston, P. G., Liang, C. M., Henry, S., Chabner, B. A., and Allegra, C. J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res., 51: 6668-6676, 1991.
32. Breuninger, L. M., Paul, S., Gaughan, K., Miki, T., Chan, A., Aaronson, S. A., and Kruh, G. D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res., 55: 5342-5347, 1995.
33. Gali, R. R., and Board, P. G. Sequencing and expression of a cDNA for human glutathione synthetase. Biochem. J., 310: 353-358, 1995.
34. Nishimura, T., Newkirk, K., Sessions, R. B., Andrews, P. A., Trock, B. J., Rasmussen, A. A., Montgomery, E. A., Bischoff, E. K., and Cullen, K. J. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin. Cancer Res., 2: 1859-1865, 1996.
35. Nelson, W. G., and Kastan, M. B. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
36. Oren, M. Relationship of p53 to the control of apoptotic cell death. Cancer Biol., 5: 221-227, 1994.
37. Eastman, A. Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells, 2: 275-280, 1990.
38. Bradford, C. R., Zhu, S., Poore, J., Fisher, S. G., Beals, T. F., Thoraval, D., Hanash, S. M., Carey, T. E., and Wolf, G. T. p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch. Otolaryngol. Head Neck Surg., 123: 605-609, 1997.
39. Ali-Osman, F., Brunner, J. M., Kutluk, T. M., and Hess, K. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin. Cancer Res., 3: 2253-2261, 1997.
40. Yokoyama, Y., Sagara, M., Sato, S., and Saito, Y. Value of glutathione S-transferase π and the oncogene products c-Jun, c-Fos, c-H-Ras, and c-Myc as a prognostic indicator in endometrial carcinomas. Gynecol. Oncol., 68: 280-287, 1998.
41. Raybaud-Diogene, H., Fortin, A., Morency, R., Roy, J., Monteil, R. A., and Tetu, B. Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study. J. Clin. Oncol., 15: 1030-1038, 1997.
42. Silvestrini, R., Daidone, M. G., Veneroni, S., Benini, E., Scarfone, G., Zanaboni, F., Villa, A., Presti, M., Danese, S., and Bolis, G. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer (Phila.), 82: 159-167, 1998.
43. Boku, N., Chin, K., Hosokawa, K., Ohtsu, A., Tajiri, H., Yoshida, S., Yamao, T., Kondo, H., Shirao, K., Shimada, Y., Saito, D., Hasebe, T., Mukai, K., Seki, S., Saito, H., and Johnston, P. G. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin. Cancer Res., 4: 1469-1474, 1998.